Benralizumab is a humanized monoclonal antibody used primarily in the treatment of severe eosinophilic asthma in patients aged 12 years and older whose condition is uncontrolled despite standard therapies. It specifically binds to the alpha subunit of the interleukin-5 (IL-5) receptor on the surface of eosinophils and basophils, blocking IL-5 signaling and promoting eosinophil depletion through antibody-dependent cell-mediated cytotoxicity (ADCC). By reducing eosinophil levels, benralizumab helps control asthma symptoms, decrease the frequency of exacerbations, improve lung function, and reduce the need for oral corticosteroids, thereby minimizing long-term steroid-related side effects. It is administered via subcutaneous injection, typically every four weeks for the first three doses, followed by every eight weeks thereafter, offering a convenient option for long-term management.